Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
July 8, 2024Frontiers in OncologyOpen Access

Camrelizumab combined with anlotinib as second-line therapy for metastatic or recurrent small cell lung cancer: a retrospective cohort study

View Full Paper
Ask AI
Bookmark
Share

Authors

SSShujing ShenZhengzhou UniversityXLXingya LiBeijing VDJBio (China)SGSanxing GuoFirst Affiliated Hospital of Zhengzhou University

Discussion

Loading...

Member takes

Implication

Key Points

Key points are not available for this paper at this time.

Cite This Study

Shen et al. (2024) studied this question.

synapsesocial.com/papers/68e60f70b6db6435875a2e56https://doi.org/10.3389/fonc.2024.1391828
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Topotecan, a new active drug in the second-line treatment of small-cell lung cancer: a phase II study in patients with refractory and sensitive disease. The European Organization for Research and Treatment of Cancer Early Clinical Studies Group and New Drug Development Office, and the Lung Cancer Cooperative Group.1997 · 481 citations
  2. 2Anlotinib: a novel multi-targeting tyrosine kinase inhibitor in clinical development2018 · 692 citations
  3. 3Bevacizumab plus Ipilimumab in Patients with Metastatic Melanoma2014 · 606 citations
  4. 4Medical management of lung cancer: Experience in C hina2014 · 40 citations
  5. 5Pembrolizumab plus Chemotherapy in Metastatic Non–Small-Cell Lung Cancer2018 · 6,791 citations